Oncology News

Between 2012 and 2019, esophageal cancer rates nearly doubled and prevalence of Barrett’s esophagus increased by 50% among adults aged 45 to 64 years, according to researchers.

Colorectal cancer is the third leading cause of cancer-related deaths in the United States, for both men and women, and across the entire population represents the second most common cause of cancer deaths and diagnoses.

Women who initiated endoscopy screening before age 50 years demonstrated a significantly reduced risk for colorectal cancer than women who did not undergo endoscopy, according to study results published in JAMA Oncology.

In this Healio video exclusive, Mark A. Molos, MD, of WestGlen Gastrointestinal Consultants in Shawnee, Kansas, discusses his experience with the GI OnDEMAND genetic testing program from Ambry Genetics.

Gemcitabine and cisplatin plus durvalumab, with or without tremelimumab, produced favorable outcomes as first-line treatment for advanced biliary tract cancer, according to research.

The FDA granted priority review to durvalumab plus chemotherapy for treatment of locally advanced or metastatic biliary tract cancer.

The FDA has informed Hutchmed Ltd. that the data package included in a new drug application for surufatinib to treat pancreatic and extra-pancreatic neuroendocrine tumors does not support approval in the U.S., the company announced.

Among patients with T1 colorectal cancer, deep submucosal invasion was not a significant independent predictor for lymph node metastasis and should not be considered the sole indicator for oncologic surgery.

The U.S. Multi-Society Task Force on colorectal cancer published updated guidance for the diagnosis, assessment and management of patients with gastrointestinal hamartomatous polyposis syndromes, with a focus on cancer risk.

The addition of tislelizumab to chemotherapy significantly extended OS for patients with previously untreated advanced esophageal squamous cell carcinoma, according to a press release from the agent’s manufacturer.